WVP
EVOK

Worth Venture Partners’s Evoke Pharma EVOK Stock Holding History

Worth Venture Partners’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,762
Closed -$517K – 140
2021
Q3 		$517K Hold
2,762
– – 0.23% 90
2021
Q2 		$545K Buy
2,762
+425
+18% +$91K 0.2% 87
2021
Q1 		$616K Buy
+2,337
New +$935K 0.3% 76

Other funds holding EVOK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WA
Wambolt & Associates Littleton, Colorado $297M AUM 17.23% 1-Year Est. Return

Worth Venture Partners's EVOK Position: Q4 2021 in Review

Worth Venture Partners sold out of Evoke Pharma (EVOK) in Q4 2021, closing a stake of 2,762 shares — an estimated $517K sold.

Worth Venture Partners first reported a position in EVOK in Q1 2021 and held it in 3 quarters. The position peaked at $616K in Q1 2021. 23 funds tracked by Wall St. Rank hold EVOK as of Q4 2021.

  • Worth Venture Partners reported no remaining Evoke Pharma position as of Q4 2021 after selling out during the quarter.
  • Worth Venture Partners sold 2,762 Evoke Pharma shares in Q4 2021, an estimated $517K.
  • Worth Venture Partners first reported a position in Evoke Pharma in Q1 2021 and held it in 3 quarters.
  • Worth Venture Partners's Evoke Pharma position peaked at $616K in Q1 2021.
  • 23 funds tracked by Wall St. Rank held Evoke Pharma as of Q4 2021.

Based on Worth Venture Partners's 13F filing for Q4 2021, filed 14 Feb 2022.